Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].
Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, Loveland BE, Piddlesden SJ, Plebanski M, Pouniotis DS, Alexis MN, McKenzie IF, Vassilaros S
Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses.
Apostolopoulos V, Pouniotis DS, van Maanen PJ, Andriessen RW, Lodding J, Xing PX, McKenzie IF, Loveland BE, Pietersz GA
Novel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivity.
Newcombe NG, Beagley LG, Christiansen D, Loveland BE, Johansson ES, Beagley KW, Barry RD, Shafren DR
Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons.
Loveland BE, Milland J, Kyriakou P, Thorley BR, Christiansen D, Lanteri MB, Regensburg M, Duffield M, French AJ, Williams L, Baker L, Brandon MR, Xing PX, Kahn D, McKenzie IF
CD46 protects pig islets from antibody but not cell-mediated destruction in the mouse.
McKenzie IF, Li YQ, Xing PX, Dinatale I, Koulmanda M, Loveland BE, Sandrin MS